netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Search
 Results

Looking for Aflibercept found 9 matches

Open monograph to display formulary status BNF Category
  Restricted Drug Aflibercept  (Eylea) Eye - Subfoveal choroidal neovascularisation - 11.08.02
  Cytotoxic Drug Aflibercept  (Zaltrap) Malignant disease and immunosuppression - Cytotoxic drugs - 08.01
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA294: Macular degeneration (wet age-related) - aflibercept (11.08.02)
link in drug section NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (11.08.02)
link in drug section NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy  (08.01)
link in drug section NICE TA346: Aflibercept for treating diabetic macular oedema (11.08.02)
link in drug section NICE TA409 : Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (11.08.02)
link in drug section NICE TA486: Aflibercept for treating choroidal neovascularisation (11.08.02)
link in drug section TA307 - Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (08.01.05)


 

netFormulary